Glutaminolysis: A Hallmark of Cancer Metabolism

Annual Review of Biomedical Engineering

Volumn 19, Issue , 2017, Pages 163-194

  Yang, Lifeng ^a,b   Venneti, Sriram ^c   Nagrath, Deepak ^a,b,d,e  

^a RICE UNIVERSITY   (United States)

^b Rice University   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Biosynthesis; Cancer; Global methylation; Glutaminolysis; Metabolic imaging; Metastasis; PET imaging; Proliferation; Tumor microenvironment

Indexed keywords

ALKYLATION; AMINO ACIDS; BIOCHEMISTRY; BIOSYNTHESIS; CELL SIGNALING; CYTOLOGY; DISEASES; FATTY ACIDS; METABOLISM; METHYLATION; PATHOLOGY; PATIENT TREATMENT; PHYSIOLOGY; TUMORS;

CANCER; GLUTAMINOLYSIS; METABOLIC IMAGING; METASTASIS; PET IMAGING; PROLIFERATION; TUMOR MICROENVIRONMENT;

CELLS;

ANTINEOPLASTIC AGENT; CARBON; GLUTAMINE; NITROGEN; NONESSENTIAL AMINO ACID; PURINE DERIVATIVE; PYRIMIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TUMOR MARKER;

AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; AMINO ACID TRANSPORT; ARTICLE; AUTOPHAGY; CANCER CELL; CARBOHYDRATE METABOLISM; CITRIC ACID CYCLE; DRUG TARGETING; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GLUTAMINOLYSIS; GLUTATHIONE METABOLISM; HUMAN; INTRACELLULAR SIGNALING; ISOTOPE LABELING; MALIGNANT NEOPLASM; METASTASIS; NITROGEN METABOLISM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOGENE; POSITRON EMISSION TOMOGRAPHY; PURINE METABOLISM; PYRIMIDINE METABOLISM; RESPIRATORY CHAIN; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; ANIMAL; BIOLOGICAL MODEL; CELL PROLIFERATION; CELL TRANSFORMATION; METABOLISM; MITOCHONDRION; NEOPLASM; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GLUTAMINE; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85021169322     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-071516-044546     Document Type: Article

References (176)

1. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144: 646-74
2. Pavlova NN, Thompson CB. 2016. The emerging hallmarks of cancermetabolism. CellMetab. 23: 27-47
3. Warburg O. 1956. On the origin of cancer cells. Science 123: 309-14
4. Warburg O. 1956. On respiratory impairment in cancer cells. Science 124: 269-70
5. Lunt SY, Vander Heiden MG. 2011. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27: 441-64
6. Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E, et al. 2013. The protooncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol. Cell 51: 236-48
7. Zheng L, Cardaci S, Jerby L, Mackenzie ED, Sciacovelli M, et al. 2015. Fumarate induces redoxdependent senescence by modifying glutathione metabolism. Nat. Commun. 6: 4001
8. Cardaci S, Zheng L, Mackay G, Van Den Broek NJF, Mackenzie ED, et al. 2015. Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. 17: 1317-26
9. Bricker DK, Taylor EB, Schell JC, Orsak T, Boutron A, et al. 2012. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 337: 96-100
10. Porporato PE, Payen VL, Pérez-Escuredo J, De Saedeleer CJ, Danhier P, et al. 2014. A mitochondrial switch promotes tumor metastasis. Cell Rep. 8: 754-66
11. Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM. 2015. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162: 540-51
12. Fantin VR, Leder P. 2006. Mitochondriotoxic compounds for cancer therapy. Oncogene 25: 4787-97
13. Smolke CD. 2010. The Metabolic Pathway Engineering Handbook: Fundamentals. Boca Raton, FL: CRC/Taylor & Francis
14. Eagle H. 1955. The minimum vitamin requirements of the L and HeLa cells in tissue culture, the production of specific vitamin deficiencies, and their cure. J. Exp. Med. 102: 595-600
15. Fan J, Kamphorst JJ, Mathew R, Chung MK, White E, et al. 2013. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol. Syst. Biol. 9: 712
16. Yang L, Moss T, Mangala LS, Marini J, Zhao H, et al. 2014. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol. Syst. Biol. 10: 728-728
17. vanGeldermalsen M, Wang Q, NagarajahR, Marshall AD, Thoeng A, et al. 2016. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene 35: 3201-8
18. Hamberger A, Nyström B, Larsson S, Silfvenius H, Nordborg C. 1991. Amino acids in the neuronal microenvironment of focal human epileptic lesions. Epilepsy Res. 9: 32-43
19. Bode BP, SoubaWW. 1999. Glutamine transport and human hepatocellular transformation. J. Parenter. Enter. Nutr. 23(5 Suppl.): S33-37
20. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, et al. 2007. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. PNAS 104: 19345-50
21. Sellers K, Fox MP, Bousamra M, Slone SP, Higashi RM, et al. 2015. Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J. Clin. Investig. 125: 687-98
22. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, et al. 2011. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. PNAS 108: 8674-79
23. Kowalski TJ, Watford M. 2016. By rat subcutaneous adipose tissue in vivo production of glutamine and utilization of glutamate production of glutamine and utilization of glutamate by rat subcutaneous adipose tissue in vivo. Am. J. Physiol. Endocrinol. Metab. 266: E151-54
24. Mittendorfer B, Volpi E, Wolfe RR. 2001. Whole body and skeletal muscle glutamine metabolism in healthy subjects. Am. J. Physiol. Endocrinol. Metab. 280: E323-33
25. Klimberg VS, Souba WW, Salloum RM, Plumley DA, Cohen FS, et al. 1990. Glutamine-enriched diets support muscle glutamine metabolism without stimulating tumor growth. J. Surg. Res. 48: 319-23
26. Maggs DG, Jacob R, Rife F, Lange R, Leone P, et al. 1995. Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricepmuscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle. J. Clin. Investig. 96: 370-77
27. Patterson BW, Horowitz JF, Wu G, Watford M, Coppack SW, Klein S. 2002. Regional muscle and adipose tissue amino acid metabolism in lean and obese women. Am. J. Physiol. Endocrinol. Metab. 282: E931-36
28. Ehsanipour EA, Sheng X, Behan JW, Wang X, Butturini A, et al. 2013. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res. 73: 2998-3006
29. Daikhin Y, YudkoffM. 2000. Glutamate and glutamine in the brain compartmentation of brain glutamate metabolism in neurons and glia. J. Nutr. 130: 1026-31
30. Stumvoll M, Perriello G, Meyer C, Gerich J. 1999. Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int. 55: 778-92
31. Palmieri EM, Spera I, Menga A, Infantino V, Iacobazzi V, Castegna A. 2014. Glutamine synthetase desensitizes differentiated adipocytes to proinflammatory stimuli by raising intracellular glutamine levels. FEBS Lett. 588: 4807-14
32. Garber AJ. 1978. The regulation of skeletal muscle alanine and glutamine formation and release in experimental chronic uremia in the rat subsensitivity of adenylate cyclase and amino acid release to epinephrine and serotonin. J. Clin. Investig. 62: 633-41
33. Häussinger D, Sies H, ed. 1984. Glutamine Metabolism in Mammalian Tissues. Berlin/Heidelberg: Springer
34. Felig P, Wahrent J, Raft L. 1973. Evidence of inter-organ amino-acid transport by blood cells in humans. PNAS 70: 1775-79
35. Häussinger D, Graf D, Weiergräber OH. 2001. Glutamine and cell signaling in liver. J. Nutr. 131(9 Suppl.): S2509-24
36. Matsuno T, Goto L. 1992. Glutaminase and glutamine synthetase activities in human cirrhotic liver and hepatocellular carcinoma. Cancer Res. 52: 1192-94
37. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, et al. 2013. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496: 101-5
38. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang X-Y, et al. 2008. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. PNAS 105: 18782-87
39. Gao P, Tchernyshyov I, Chang T-C, Lee Y-S, Kita K, et al. 2009. c-Myc suppression of mir-23 enhances mitochondrial glutaminase and glutamine metabolism. Nature 458: 762-65
40. Mannava S, Grachtchouk V, Wheeler LJ, Im M, Zhuang D, et al. 2008. Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle 7: 2392-400
41. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, et al. 2014. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 7: 523-23
42. Csibi A, Fendt S-M, Li C, Poulogiannis G, Choo AY, et al. 2013. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153: 840-54
43. Bryan HK, Olayanju A, Goldring CE, Park BK. 2013. The NRF2 cell defence pathway: KEAP1-dependent and-independent mechanisms of regulation. Biochem. Pharmacol. 85: 705-17
44. Wu KC, Cui JY, Klaassen CD. 2011. Beneficial role of NRF2 in regulating NADPH generation and consumption. Toxicol. Sci. 123: 590-600
45. Lane DP. 1992. p53, guardian of the genome. Nature 358: 15-16
46. Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, et al. 2010. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. PNAS 107: 7461-66
47. Reynolds MR, Lane AN, Robertson B, Kemp S, Liu Y, et al. 2014. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene 33: 556-66
48. Faubert B, Vincent EE, Griss T, Samborska B, Izreig S, et al. 2014. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1. PNAS 111: 2554-59
49. Hung C-L, Wang L-Y, Yu Y-L, Chen H-W, Srivastava S, et al. 2014. A long noncoding RNA connects c-Myc to tumor metabolism. PNAS 111: 18697-702
50. Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, et al. 2016. Allele-specific reprogramming of cancer metabolism by the long non-coding RNA CCAT2. Mol. Cell 61: 520-34
51. Jeon YJ, Khelifa S, Ratnikov B, Scott DA, Feng Y, et al. 2015. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. Cancer Cell 27: 354-69
52. Langley RR, Fidler IJ. 2011. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer. 128: 2527-35
53. Venmar KT, Kimmel DW, Cliffel DE, Fingleton B. 2015. IL4 receptor mediates enhanced glucose and glutamine metabolism to support breast cancer growth. Biochim. Biophys. Acta 1853: 1219-28
54. Wellen KE, Lu C, Mancuso A, Lemons JMS, Ryczko M, et al. 2010. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev. 24: 2784-99
55. Blagih J, Coulombe F, Vincent EE, Dupuy F, Galicia-Vázquez G, et al. 2015. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42: 41-54
56. Wang R, Dillon CP, Shi LZ, Milasta S, Carter R, et al. 2011. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35: 871-82
57. Semenza GL. 2013. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Investig. 123: 3664-71
58. Sun RC, Denko NC. 2014. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab. 19: 285-92
59. Pérez-Escuredo J, Dadhich RK, Dhup S, Cacace A, VanHée VF, et al. 2015. Lactate promotes glutamine uptake and metabolism in oxidative cancer cells. Cell Cycle 15: 72-83
60. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, et al. 2014. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13: 890-901
61. Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, et al. 2015. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J. Clin. Investig. 125: 1591-602
62. Williams JC, Kizaki H, Weber G, Morris HP. 1978. Increased CTP synthetase activity in cancer cells. Nature 271: 71-73
63. Lunt SY, Muralidhar V, Hosios AM, Israelsen WJ, Gui DY, et al. 2015. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol. Cell 57: 95-107
64. Son J, Lyssiotis CA, Ying H, Wang X, Hua S, et al. 2013. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496: 101-5
65. Sullivan LB, Gui DY, Hosios AM, Bush LN, Freinkman E, Vander Heiden MG. 2015. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell 162: 552-63
66. Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM. 2015. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162: 540-51
67. Locasale JW. 2013. Serine, glycine and one-carbon units: cancer metabolism in full circle. Nat. Rev. Cancer 13: 572-83
68. Ahn CS, Metallo CM. 2015. Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab. 3: 1
69. Tessem M-B, Swanson MG, Keshari KR, Albers MJ, Joun D, et al. 2008. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn. Reson. Med. 60: 510-16
70. Coloff JL, Murphy JP, Braun CR, Harris IS, Shelton LM, et al. 2016. Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. Cell Metab. 23: 867-80
71. Li BS, Gu LJ, Luo CY, Li WS, Jiang LM, et al. 2006. The downregulation of asparagine synthetase expression can increase the sensitivity of cells resistant to L-asparaginase. Leukemia 20: 2199-201
72. Samudio I, Konopleva M. 2013. Asparaginase unveils glutamine-addicted AML. Blood 122: 3398-400
73. Zhang J, Fan J, Venneti S, Cross JR, Takagi T, et al. 2014. Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol. Cell 56: 205-18
74. Jones ME. 1985. Conversion of glutamate to ornithine and proline: pyrroline-5-carboxylate, a possible modulator of arginine requirements. J. Nutr. 115: 509-15
75. Iwashita Y, Sakiyama T, Musch MW, Ropeleski MJ, Tsubouchi H, Chang EB. 2011. Polyamines mediate glutamine-dependent induction of the intestinal epithelial heat shock response. Am. J. Physiol. Gastrointest. Liver Physiol. 301: G181-87
76. Wojcik M, Seidle HF, Bieganowski P, Brenner C. 2006. NAD+ synthetase. How a two-domain, threesubstrate enzyme avoids waste. J. Biol. Chem. 281: 33395-402
77. Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP. 1996. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 56: 1189-93
78. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, et al. 2011. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481: 380-84
79. Dang L, WhiteDW, Gross S, Bennett BD, Bittinger MA, et al. 2009. Cancer-associated IDH1mutations produce 2-hydroxyglutarate. Nature 462: 739-44
80. Jiang L, Shestov AA, Swain P, Yang C, Parker SJ, et al. 2016. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532: 255-58
81. MullenAR, WheatonWW, JinES, Chen P-H, Sullivan LB, et al. 2011. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481: 385-88
82. Wise DR, Ward PS, Shay JES, Cross JR, Gruber JJ, et al. 2011. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of ketoglutarate to citrate to support cell growth and viability. PNAS 108: 19611-16
83. Fendt S-M, Bell EL, KeiblerMA, OlenchockBA, Mayers JR, et al. 2013. Reductive glutaminemetabolism is a function of the ketoglutarate to citrate ratio in cells. Nat. Commun. 4: 2236
84. Mullen AR, Hu Z, Shi X, Jiang L, Boroughs LK, et al. 2014. Oxidation of ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep. 7: 1679-90
85. Weinberg F, Hamanaka R, WheatonWW, Weinberg S, Joseph J, et al. 2010. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. PNAS 107: 8788-93
86. Pfau SJ, Amon A. 2012. Chromosomal instability and aneuploidy in cancer: from yeast to man. EMBO Rep. 13: 515-27
87. Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD. 2014. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510: 298-302
88. Ying H, Kimmelman AC, Lyssiotis CA, Hua S, ChuGC, et al. 2012. OncogenicKrasmaintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149: 656-70
89. Martnez-Reyes I, Chandel NS. 2014. Mitochondrial one-carbon metabolism maintains redox balance during hypoxia. Cancer Discov. 4: 1371-73
90. Cairns RA, Harris IS, Mak TW. 2011. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11: 85-95
91. Wallace DC. 2012. Mitochondria and cancer. Nat. Rev. Cancer 12: 685-98
92. Jeon S-M, Chandel NS, Hay N. 2012. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 485: 661-65
93. Conrad M, Sato H. 2012. The oxidative stress-inducible cystine/glutamate antiporter, system xc : cystine supplier and beyond. Amino Acids 42: 231-46
94. Kim D-H, Sarbassov DD, Ali SM, King JE, Latek RR, et al. 2002. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-75
95. Kim J, Guan K-L. 2011. Amino acid signaling in TOR activation. Annu. Rev. Biochem. 80: 1001-32
96. Cohen A, Hall MN. 2009. An amino acid shuffle activates mTORC1. Cell 136: 399-400
97. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, et al. 2009. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136: 521-34
98. Carobbio S, Frigerio F, Rubi B, Vetterli L, Bloksgaard M, et al. 2009. Deletion of glutamate dehydrogenase in cells abolishes part of the insulin secretory response not required for glucose homeostasis. J. Biol. Chem. 284: 921-29
99. Duran RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, et al. 2012. Glutaminolysis activates Rag-mTORC1 signaling. Mol. Cell 47: 349-58
100. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, et al. 2008. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320: 1496-501
101. Kim SG, Hoffman GR, Poulogiannis G, Buel GR, Jang YJ, et al. 2013. Metabolic stress controls mTORC1 lysosomal localization and dimerization by regulating the TTT-RUVBL1/2 complex. Mol. Cell 49: 172-85
102. Fernandez-Marcos PJ, Serrano M. 2013. Sirt4: the glutamine gatekeeper. Cancer Cell 23: 427-28
103. Jeong SM, Xiao C, Finley LWS, Lahusen T, Souza AL, et al. 2013. Sirt4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 23: 450-63
104. Shanware NP, Bray K, Eng CH, Wang F, Follettie M, et al. 2014. Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion. Nat. Commun. 5: 4900
105. Fumarola C, Zerbini A, Guidotti GG. 2001. Glutamine deprivation-mediated cell shrinkage induces ligand-independent CD95 receptor signaling and apoptosis. Cell Death Differ. 8: 1004-13
106. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. 2007. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol. 178: 93-105
107. Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, et al. 2013. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLOS ONE 8: e81162
108. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, et al. 2012. Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-83
109. Rocha CRR, Garcia CCM, Vieira DB, Quinet A, de Andrade-Lima LC, et al. 2014. Glutathione depletion sensitizes cisplatin-and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis. 5: e1505
110. WangW, Kryczek I, DostáL, MunkarahA, Liu JR, et al. 2016. EffectorTcells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell 165: 1-14
111. Calorini L, Bianchini F. 2010. Environmental control of invasiveness and metastatic dissemination of tumor cells: the role of tumor cell-host cell interactions. Cell Commun. Signal. 8: 24
112. LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, et al. 2014. PGC-1mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16: 992-1003
113. Santidrian AF, Matsuno-Yagi A, Ritland M, Seo BB, LeBoeuf SE, et al. 2013. Mitochondrial complex I activity and NAD+/NADH balance regulate breast cancer progression. J. Clin. Investig. 123: 1068-81
114. Liu G, Zhu J, Yu M, Cai C, Zhou Y, et al. 2015. Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients. J. Transl. Med. 13: 144
115. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-12
116. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360: 765-73
117. Ward PS, Patel J, Wise DR, Abdel-WahabO, Bennett BD, et al. 2010. The common feature of leukemiaassociated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225-34
118. Xu W, Yang H, Liu Y, Yang Y, Wang P, et al. 2011. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of ketoglutarate-dependent dioxygenases. Cancer Cell 19: 17-30
119. Carey BW, Finley LWS, Cross JR, Allis CD, Thompson CB. 2014. Intracellular ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518: 413-16
120. Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, et al. 2011. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. PNAS 108: 314-18
121. Xiao M, Yang H, Xu W, Ma S, Lin H, et al. 2012. Inhibition of KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 26: 1326-38
122. Intlekofer AM, Dematteo RG, Venneti S, Finley LWS, Lu C, et al. 2015. Hypoxia induces production of L-2-hydroxyglutarate. Cell Metab. 22: 304-11
123. Oldham WM, Clish CB, Yang Y, Loscalzo J. 2015. Hypoxia-mediated increases in L-2-hydroxyglutarate coordinate the metabolic response to reductive stress. Cell Metab. 22: 291-303
124. Shi Y, Thrippleton MJ, Makin SD, Marshall I, Geerlings MI, et al. 2016. Cerebral blood flow in small vessel disease: a systematic review and meta-analysis. J. Cereb. Blood Flow Metab. 36: 1653-67
125. Burgering BM, Coffer PJ. 1995. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376: 599-602
126. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, et al. 1998. Protein kinase B kinases that mediate phosphatidylinositol 3, 4, 5-trisphosphate-dependent activation of protein kinase B. Science 279: 710-14
127. van der Vos KE, Eliasson P, Proikas-Cezanne T, Vervoort SJ, van Boxtel R, et al. 2012. Modulation of glutamine metabolism by the PI(3)K-PKB-FOXO network regulates autophagy. Nat. Cell Biol. 14: 829-37
128. Bott AJ, Peng I-C, Fan Y, Faubert B, Zhao L, et al. 2015. OncogenicMyc induces expression of glutamine synthetase through promoter demethylation. Cell Metab. 22: 1068-77
129. Kung H-N, Marks JR, Chi J-T. 2011. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLOS Genet. 7: e1002229
130. MeleyD, Bauvy C, Houben-Weerts JHPM, Dubbelhuis PF, HelmondMTJ, et al. 2006. AMP-activated protein kinase and the regulation of autophagic proteolysis. J. Biol. Chem. 281: 34870-79
131. White E. 2015. The role for autophagy in cancer. J. Clin. Investig. 125: 42-46
132. Levine B, Packer M, Codogno P. 2015. Development of autophagy inducers in clinical medicine. J. Clin. Investig. 12514-24
133. Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, et al. 2013. Autophagy sustains mitochondrial glutaminemetabolism and growth of BRAFV600E-driven lung tumors. Cancer Discov. 3: 1272-85
134. Kamphorst JJ, Cross JR, Fan J, de Stanchina E, Mathew R, et al. 2013. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. PNAS 110: 8882-87
135. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, et al. 2013. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497: 633-37
136. Zhao H, Yang L, Baddour J, Achreja A, Bernard V, et al. 2016. Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism. eLife 5: e10250
137. Hanahan D, Coussens LM. 2012. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21: 309-22
138. Martinez-Outschoorn UE, Lisanti MP, Sotgia F. 2014. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin. Cancer Biol. 25: 47-60
139. Lisanti MP, Martinez-Outschoorn UE, Sotgia F. 2013. Oncogenes induce the cancer-associated fibroblast phenotype: Metabolic symbiosis and "fibroblast addiction" are new therapeutic targets for drug discovery. Cell Cycle 12: 2723-32
140. Yang L, Achreja A, Yeung TL, Mangala LS, JiangD, et al. 2016. Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab. 24: 685-700
141. Kelloff GJ, Hoffman JM, Johnson B, ScherHI, Siegel BA, et al. 2005. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin. Cancer Res. 11: 2785-808
142. Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, et al. 1985. Prediction of survival in glioma patients by means of positron emission tomography. J. Neurosurg. 62: 816-22
143. Wang J-H, Chen W-L, Li J-M, Wu S-F, Chen T-L, et al. 2013. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. PNAS 110: 17017-22
144. Lieberman BP, Ploessl K, Wang L, Qu W, Zha Z, et al. 2011. PET imaging of glutaminolysis in tumors by 18F-(2S, 4R)4-fluoroglutamine. J. Nucl. Med. 52: 1947-55
145. Qu W, Zha Z, Ploessl K, Lieberman BP, Zhu L, et al. 2011. Synthesis of optically pure 4-fluoroglutamines as potential metabolic imaging agents for tumors. J. Am. Chem. Soc. 133: 1122-33
146. Wu Z, Zha Z, Li G, Lieberman BP, Choi SR, et al. 2014. [18F](2S, 4S)-4-(3-Fluoropropyl)glutamine as a tumor imaging agent. Mol. Pharm. 11: 3852-66
147. Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, et al. 2015. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Sci. Transl. Med. 7: 274ra17
148. Ploessl K, Wang L, Lieberman BP, Qu W, Kung HF. 2012. Comparative evaluation of 18F-labeled glutamic acid and glutamine as tumor metabolic imaging agents. J. Nucl. Med. 53: 1616-24
149. Glunde K, Bhujwalla ZM. 2011. Metabolic tumor imaging using magnetic resonance spectroscopy. Semin. Oncol. 38: 26-41
150. Griffin JL, Shockcor JP. 2004. Metabolic profiles of cancer cells. Nat. Rev. Cancer 4: 551-61
151. Hertz L, Dringen R, Schousboe A, Robinson SR. 1999. Astrocytes: glutamate producers for neurons. J. Neurosci. Res. 57: 417-28
152. Chawla S, Oleaga L, Wang S, Krejza J, Wolf RL, et al. 2010. Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J. Neuroimaging 20: 3-8
153. Chawla S, Wang S, Wolf RL, Woo JH, Wang J, et al. 2007. Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. Am. J. Neuroradiol. 28: 1683-89
154. Majós C, Julià-Sapé M, Alonso J, Serrallonga M, Aguilera C, et al. 2004. Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. Am. J. Neuroradiol. 25: 1696-704
155. Wilson M, Gill SK, MacPherson L, EnglishM, Arvanitis TN, Peet AC. 2014. Noninvasive detection of glutamate predicts survival in pediatric medulloblastoma. Clin. Cancer Res. 20: 4532-39
156. Buescher JM, Antoniewicz MR, Boros LG, Burgess SC, Brunengraber H, et al. 2015. A roadmap for interpreting 13C metabolite labeling patterns from cells. Curr. Opin. Biotechnol. 34: 189-201
157. Yuneva MO, Fan TWM, Allen TD, Higashi RM, Ferraris DV, et al. 2012. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 15: 157-70
158. Marin-Valencia I, Yang C, MashimoT, Cho S, Baek H, et al. 2012. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 15: 827-37
159. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, et al. 2014. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159: 1603-14
160. Davidson SM, Papagiannakopoulos T, OlenchockBA, HeymanJE, KeiblerMA, et al. 2016. Environment impacts the metabolic dependencies of Ras-driven non-small-cell lung cancer. Cell Metab. 23: 517-28
161. Tardito S, Oudin A, Ahmed SU, Fack F, Keunen O, et al. 2015. Glutamine synthetase activity fuels nucleotide biosynthesis and supports growth of glutamine-restricted glioblastoma. Nat. Cell Biol. 17: 1556-68
162. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark AL, et al. 2013. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-13C]pyruvate. Sci. Transl. Med. 5: 198ra108
163. Wilson DM, Kurhanewicz J. 2014. Hyperpolarized 13C MR for molecular imaging of prostate cancer. J. Nucl. Med. 55: 1567-72
164. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, et al. 2003. Increase in signal-tonoise ratio of >10, 000 times in liquid-state NMR. PNAS 100: 10158-63
165. Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM. 2008. 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn. Reson. Med. 60: 253-57
166. Cabella C, KarlssonM, Canapè C, Catanzaro G, Colombo Serra S, et al. 2013. In vivo and in vitro liver cancer metabolism observed with hyperpolarized [5-13C]glutamine. J. Magn. Reson. 232: 45-52
167. Barb AW, Hekmatyar SK, Glushka JN, Prestegard JH. 2011. Exchange facilitated indirect detection of hyperpolarized 15ND2-amido-glutamine. J. Magn. Reson. 212: 304-10
168. Hassanein M, Hoeksema MD, Shiota M, Qian J, Harris BK, et al. 2013. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival. Clin. Cancer Res. 19: 560-70
169. Hassanein M, Qian J, Hoeksema MD, Wang J, JacobovitzM, et al. 2015. Targeting SLC1A5-mediated glutamine dependence in non-small-cell lung cancer. Int. J. Cancer 137: 1587-97
170. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, et al. 2007. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 406: 407-14
171. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, et al. 2014. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol. Cancer Ther. 13: 890-901
172. Wang J-B, Erickson JW, Fuji R, Ramachandran S, Gao P, et al. 2010. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 18: 207-19
173. Wilson KF, Erickson JW, Antonyak MA, Cerione RA. 2013. Rho GTPases and their roles in cancer metabolism. Trends Mol. Med. 19: 74-82
174. Li C, Allen A, Kwagh J, Doliba NM, Qin W, et al. 2006. Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase. J. Biol. Chem. 281: 10214-21
175. Korangath P, TeoWW, SadikH, Han L, Mori N, et al. 2015. Targeting glutamine metabolism in breast cancer with aminooxyacetate. Clin. Cancer Res. 3263-73
176. Farber S, Diamond LK, Mercer RD, Sylvester RFJ, Wolff JA. 1948. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N. Engl. J. Med. 238: 787-93